FIGURE 5.

Treatment beyond progression may control tumor burden after nontarget progression on pembrolizumab. (a) Median tumor burden in patients from a representative trial replicate receiving pembrolizumab beyond progression (red) or salvage chemotherapy (cyan). Shaded regions represent the interquartile range at each timepoint. (b) Same as (a) for patients with target progression without nontarget progression. (c) Same as (a) for patients with nontarget progression without target progression. (d) Same as (a) for patients with simultaneous target and nontarget progression